Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A · SSE:600276
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A — Merger or Acquisition (May 2026)
10 slides from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A's merger presentation, May 12, 2026
Slide 1: Hengrui + Bristol Myers Squibb Landmark Collaboration
Hengrui + Bristol Myers Squibb Landmark Collaboration Accelerating our globalization strategy May 12, 2026
Slide 2: Disclaimer
Disclaimer THIS DOCUMENT IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT INTENDED TO BE, AND SHALL NOT BE CONSTRUED AS, AN OFFER, INDUCEMENT, INVITATION, SOLICITATION, COMMITMENT OR ADVERTISEMENT WITH RESPECT TO THE PURCHASE, SUBSCRIPTION OR SALE OF ANY SECURITY AND NO PART OF IT SHALL FORM THE BASIS
Slide 3: Landmark Strategic Collaboration with Global Impact
Landmark Strategic Collaboration with Global Impact Upfront Payment + Anniversary Payments1 Total Deal Value2 $950M ($600M + up to $350M) Up to $15.2B 13 Innovative Assets in Joint R&D to Advance Global Co-Co Option on Oncology, Hematology Novel Assets Select Programs3 and Immunology Hengrui to expe
Slide 4: Long-Term Collaboration to Maximize Value of Next-Gen Pipeline Assets
Long-Term Collaboration to Maximize Value of Next-Gen Pipeline Assets Seamless End-to-End Collaboration Multi-Dimensional Programs Research Development Commercialization • Oncology and hematology 4 Hengrui Assets • FIC/BIC potential up to Clinical PoC • BMS obtains ex-China1 rights • Immunology, FIC
Slide 5: Global Alliance Combines Shared Vision and Deep Commitment
Global Alliance Combines Shared Vision and Deep Commitment • Sustained R&D commitment – 25~30% of • Differentiated research platforms anchored in causal revenue | 5,600+ talents | 15 global centers human biology | Three Platforms (TPD, CT, RPT) and multiple modalities Strong • Robust discovery engin
Slide 6: Key Financial Terms
Key Financial Terms Upfront and Anniversary Long-Term Royalty Total Deal Size Milestone Payments Payments Income Up to Upfront: $600M Development, regulatory Tiered royalties (up to Anniversary payments and commercial double-digit) on net sales $15.2B1 through 2028: up to $350M milestones: up to $14
Slide 7: Partnerships Drive Sustainable Growth and Global Reach
Partnerships Drive Sustainable Growth and Global Reach In the last three years, BD has accelerated our globalization Nature of Financial Partner Downstream the asset(s) implications alignment value Out-licensing (Leading MNC/Biotechs) NewCo (Top-tier PE/VCs) Strategic Alliance (MNCs) | Lp(a) inhibit
Slide 8: Key Takeaways
Key Takeaways Unlocking Global Value of Next-Level Integrated Accelerating Differentiated Pipeline Collaboration Globalization and Platforms • A giant step forward that delivers • Boosts innovation and • Global operation with Co-Co on Hengrui’s strategic imperative accelerates the delivery of opport
Slide 9: Q&A
Q&A
Slide 10: Unmet Medical Needs, Innovation, Globalization
Unmet Medical Needs Innovation Globalization Notes:
Jiangsu Hengrui Pharmaceuticals — Merger or Acquisition (May 2026) on 6ix